OS Therapies to Participate in Upcoming Investor Conferences in September 2025September 03, 2025 7:40 AM EDT | Source: OS TherapiesNew York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will participate in the upcoming investor conferences:Cantor Global Healthcare Conference 2025 being held September 3-5, ...

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He ...

Core Insights - Purple Biotech is advancing the development of a tri-specific antibody targeting TROP2, which is part of its CAPTN-3 platform aimed at overcoming tumor immune evasion and drug resistance [1][2][8] - The company plans to submit an Investigational New Drug (IND) application for its first CAPTN-3 tri-specific antibody, IM1240, in 2026 [1] - Encouraging preclinical results have shown sustained tumor regression in human triple negative breast cancer (TNBC) models, with significant cell death in various tumor types at low doses [4][5] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance [8] - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [8][9] - The CAPTN-3 platform utilizes a unique mechanism of action that engages both innate and adaptive immune systems to enhance anti-tumoral responses [8] Technology and Mechanism - The tri-specific antibody IM1305 includes a masked anti-CD3 arm designed to reduce off-target effects while enhancing efficacy in the tumor microenvironment [3][6] - TROP2 is expressed in various solid tumors and is linked to poor prognosis, making it a significant target for therapeutic development [5][6] - The CAPTN-3 platform's ability to recruit multiple immune effectors (T and NK cells) is expected to provide a strong rationale for its effectiveness across diverse tumor types [6][7] Future Prospects - The company is optimistic about the growing interest in TROP2 as a therapeutic target and aims to leverage its technological advancements to accelerate development timelines [7] - Purple Biotech believes that its CAPTN-3 platform can generate multiple programs and expand partnership opportunities in the oncology space [7]

Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent DirectorsBURLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced the appointments of Christopher Thompson, M.D. and Ian Sheffield to its Board of Directors. These appointments build on Fractyl’s recent momentum as it advan ...

ADMA Biologics (NASDAQ: ADMA ) is a vertically integrated U.S. Immune Globulin (referred to as IG) plasma manufacturer whose earnings are growing due to two main factors that it directly controls: higher finished-goods yield from each liter of plasma and a mix shiftMy career in the world of investing began at an early age, fueled by the potential for profits, I first began investing at the age of 11 with the help of my father. I first began picking stocks by looking at what was going to logically make money ...

Core Insights - IDEAYA Biosciences has submitted an IND application to the FDA for IDE892, a potential best-in-class MTA-cooperative inhibitor of PRMT5, targeting MTAP-deleted lung cancer [1][2] - The company plans to initiate a Phase 1 dose escalation trial for IDE892 in Q4 2025 and aims to start combination trials with IDE397 in H1 2026 [1][6] Company Overview - IDEAYA is focused on precision medicine in oncology, developing transformative therapies for cancer through small-molecule drug discovery, structural biology, and bioinformatics [4] - The company has a robust pipeline targeting synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications [4] Market Opportunity - Approximately 15-20% of non-small cell lung cancer (NSCLC) cases are MTAP-deleted, presenting a significant unmet need for targeted therapies [2] - The combination of IDE892 and IDE397 is expected to enhance anti-tumor activity, creating a promising combination therapy opportunity [2][3] Upcoming Events - IDEAYA will present the preclinical profile of IDE892 and its combination rationale with IDE397 at the 10-Year Anniversary R&D Day on September 8, 2025 [6]

Core Viewpoint - Upstream Bio's verkitug has shown promising results in a Phase 2 clinical trial for CRSwNP, leading to an 18% increase in the company's stock price following the announcement [1]. Group 1: Clinical Trial Results - In the Phase 2 clinical trial, 81 adult patients with CRSwNP were randomly assigned to receive either verkitug or a placebo every 12 weeks [3]. - After 24 weeks of treatment, the verkitug group had an average reduction of 1.8 points in the nasal polyp score (NPS) compared to baseline, significantly outperforming the placebo group and achieving the trial's primary endpoint [4]. - The verkitug treatment group reported a 0.8-point reduction in nasal congestion score (NCS) from baseline, indicating improvement in secondary endpoints [4]. - Verkitug significantly reduced the need for systemic corticosteroids or nasal polyp surgery and lowered overall symptom scores [4]. - No serious adverse events were reported during the trial, indicating good safety and tolerability for verkitug [4]. Group 2: Future Development Plans - Upstream plans to continue the clinical development of verkitug after discussions with regulatory agencies and is exploring its potential in other indications, including chronic obstructive pulmonary disease (COPD) [4][6]. - The first dosing in the Phase 2 clinical trial for COPD is scheduled for July 2025, and the company is also conducting a Phase 2 trial for severe asthma, with topline data expected in Q1 2026 [6]. Group 3: Competitive Landscape - The TSLP pathway has become a significant target for treating various inflammatory diseases, including severe asthma and allergic rhinitis, with Dupixent and Tezspire being popular biologics in the market [8]. - Verkitug is expected to challenge the market position of these existing treatments due to its unique mechanism of action, directly blocking the TSLP receptor, unlike Tezspire, which targets the TSLP ligand [9]. - Upstream claims that verkitug's potency is approximately 300 times that of Tezspire, which may provide a competitive edge [9]. - Verkitug's dosing frequency of every 12 weeks offers greater convenience compared to Dupixent and Tezspire, which require administration every 2 weeks and 4 weeks, respectively, potentially enhancing its market competitiveness [9].

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), of the important September 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Biohaven securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

Core Insights - Alnylam Pharmaceuticals is recognized as one of the leading biotech companies in the industry, demonstrating strong execution and performance [1] Company Performance - The company continues to achieve results that are well above average compared to its peers, reinforcing its position in the biotech sector [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit alleges that during the class period, Alto made materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 for treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].